Key Metrics
5.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Q1
Oncology
SJR
- Q1 Oncology
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.51
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Topics Covered
- Breast cancer
- Overall survival
- Metastatic breast cancer
- Cross-sectional study
- Breast cancer screening
- Trastuzumab
- Triple-negative breast cancer
- Pathological response
- Molecular pathology
- Quality of life
- Mastectomy
- Ataxia telangiectasia mutated
- Breast cancer cells
- Eribulin
- Hormone therapy
- Progesterone receptor
- Axillary ultrasound
- Standard therapy
- Immunohistochemistry
- Breast examination
Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2836 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2009 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 16 |
| Article Processing Charges | USD 2836 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in Breast Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.
- 1 Apr 24
- Breast cancer (Dove Medical Press)
-
Full paper
Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review.
- 1 Apr 24
- Breast cancer (Dove Medical Press)
-
Full paper
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter].
- 1 Apr 24
- Breast cancer (Dove Medical Press)
-
Full paper
HER2 Low Expression in Primary Male Breast Cancer.
- 1 Mar 24
- Breast cancer (Dove Medical Press)
-
Full paper
The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients.
- 1 Mar 24
- Breast cancer (Dove Medical Press)
-
Full paper
Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer.
- 1 Mar 24
- Breast cancer (Dove Medical Press)
Scite analysis
Powered by scite_
486 articles received 5.7k citations see all
- 214 Supporting
- 5,262 Mentioning
- 38 Contrasting
Editorial notices
- 4 Retractions
- 0 Withdrawals
- 0 Corrections
- 5 Errata
- 0 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
27%
4 to 6 months
70%
7 to 9 months
3%
Above 9 months
0%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has Breast Cancer: Targets and Therapy been actively publishing?
Breast Cancer: Targets and Therapy has been in operation since 2009 till date.
What is the publishing frequency of Breast Cancer: Targets and Therapy ?
Breast Cancer: Targets and Therapy published with a Continuous publication frequency.
How many articles did Breast Cancer: Targets and Therapy publish last years ?
In 2023, Breast Cancer: Targets and Therapy published 69 articles.
What is the eISSN & pISSN for Breast Cancer: Targets and Therapy ?
For Breast Cancer: Targets and Therapy,eISSN is 1179-1314 and pISSN is1179-1314.
What is Citescore for Breast Cancer: Targets and Therapy ?
Citescore for Breast Cancer: Targets and Therapy is 5.9.
What is SNIP score for Breast Cancer: Targets and Therapy ?
SNIP score for Breast Cancer: Targets and Therapy is 1.51.
What is the SJR for Breast Cancer: Targets and Therapy ?
SJR for Breast Cancer: Targets and Therapy is Q1.
Who is the publisher of Breast Cancer: Targets and Therapy ?
DOVE MEDICAL PRESS LTD is the publisher of Breast Cancer: Targets and Therapy.